Access cutting-edge lung cancer treatment through this clinical trial at a research site in Loma Linda. Study-provided care at no cost to qualified participants.
Access lung cancer specialists in Loma Linda at no cost
This study follows strict safety protocols and ethical guidelines
All study-related lung cancer treatment provided free
This is a Phase 1b/2 study evaluating the anti-PD1 antibody, cemiplimab, in combination with either S095018 (anti-TIM3 antibody), S095024 (anti-CD73 antibody), or S095029 (anti-NKG2A antibody) in adult participants with previously untreated advanced/metastatic non-small cell lung cancer (NSCLC) with high PD-L1 expression. The study includes two parts: part A, the combination-therapy safety lead-in phase to determine the recommended dose for expansion (RDE) for S095018, S095024, and S095029 in co
Sponsor: Servier Bio-Innovation LLC
Check if you qualify for this lung cancer clinical trial in Loma Linda, CA
If you're searching for lung cancer treatment options in Loma Linda, CA, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Loma Linda research site is actively enrolling participants for this clinical trial. You'll receive care from experienced lung cancer specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.